METAP2 and cancer: Whereas the clinical benefits of METAP2 inhibition in patients with cancer and obese patients are well documented, small-molecule fumagillin-based METAP2 inhibitors can cause reversible central nervous system (CNS) toxicities and poor drug-like properties, necessitating frequent dosing (17, 18), thereby impeding their clinical development.